2 Months Ago
1 Min Read

ATRA increasing 25% today. A look at what's happening:

-2.61% 24h

Atara Biotherapeutics (ATRA) is trading 25% higher at $4.54 today. The share price is continuing an upward move today after a strong earnings beat yesterday. The company reported an EPS of $0.18 which beat analyst estimates by $1.14, and a revenue beat of $45.05M on revenue of EPS of $51.58M.

Atara Biotherapeutics has been trading between a 52-week high of $20.04 and a 52-week low of $2.83. The stock has a market cap of $424 Million.

Atara Biotherapeutics, Inc.(@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. With its lead program in Phase 3 clinical development, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Its platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors).